In a filing, Zenas Biopharma Inc revealed its Chief Executive Officer MOULDER LEON O JR acquired Company’s shares for reported $0.17 million on Feb 18 ’25. In the deal valued at $6.67 per share,25,000 shares were bought. As a result of this transaction, MOULDER LEON O JR now holds 266,155 shares worth roughly $2.43 million.
Then, Xiao Ting bought 10,000 shares, generating $77,600 in total proceeds. Upon buying the shares at $7.76, the Director now owns 47,000 shares.
Before that, MOULDER LEON O JR bought 45,000 shares. Zenas Biopharma Inc shares valued at $449,100 were divested by the Chief Executive Officer at a price of $9.98 per share. As a result of the transaction, MOULDER LEON O JR now holds 241,155 shares, worth roughly $2.2 million.
Wedbush initiated its Zenas Biopharma Inc [ZBIO] rating to an Outperform in a research note published on March 20, 2025; the price target was $35. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering ZBIO with “Buy” recommendation on December 16, 2024. Rodman & Renshaw started covering the stock on November 05, 2024. It rated ZBIO as “a Buy”.
Price Performance Review of ZBIO
On Tuesday, Zenas Biopharma Inc [NASDAQ:ZBIO] saw its stock fall -5.68% to $9.14. Over the last five days, the stock has lost -8.78%. Nevertheless, the stocks have risen 11.60% over the past one year.
Levels Of Support And Resistance For ZBIO Stock
The 24-hour chart illustrates a support level at 8.90, which if violated will result in even more drops to 8.66. On the upside, there is a resistance level at 9.59. A further resistance level may holdings at 10.04.
How much short interest is there in Zenas Biopharma Inc?
A steep rise in short interest was recorded in Zenas Biopharma Inc stocks on 2025-06-13, dropping by 5599.0 shares to a total of 4.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 4.92 million shares. There was a decline of -0.11%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 08, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
